FDA support advances biomarker for earlier, more precise Parkinson's clinical trials
The Critical Path Institute (C-Path) has published "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" ...
Aug 26, 2026
0
4









